drug · small molecule
NEOSTIGMINE METHYLSULFATE
Marketedupdated 3mo agoby $AMPH Amphastar Pharmaceuticals, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for myasthenia gravis and 1 investigational indication.
targets
Acetylcholinesterase
all catalysts(3)
approval · 3
Sep 25, 2017
approval
$AMPH20.86-0.24%
NEOSTIGMINE METHYLSULFATE — FDA approval
NEOSTIGMINE METHYLSULFATE
→
May 19, 2022
approval
$AMPH20.86-0.24%
NEOSTIGMINE METHYLSULFATE — FDA approval
NEOSTIGMINE METHYLSULFATE
→
Oct 24, 2025
approval
$AMPH20.86-0.24%
NEOSTIGMINE METHYLSULFATE — FDA approval
NEOSTIGMINE METHYLSULFATE
→
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that